Sign in
Taking peopleNo phase

TEER for Severe DMR of Low to Intermediate Surgery Risk

Key facts

Who runs it
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
160 people, planned
Started
1 Jan 2024
Expected to end
Dec 2026
Type of study
Observational
Treatments tested
  • ultrasonic cardiography (UCG)
  • TEER
Record updated
15 March 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (36)Hide the full registry criteria

Who can take part

  • age ≥ 18 years old
  • DMR ≥ grade 3+ according to UCG integrative approach, referring to the following quantitative indicators: 1) effective regurgitant orifice area (EROA) ≥0.3cm\^2; 2) regurgitant volume (RVol) ≥45ml; 3) regurgitant fraction (RF) ≥40%
  • symptomatic heart failure ( New York Heart Association (NYHA) class II-IV ), or asymptomatic heart failure with left ventricular end systolic dimension (LVESd) ≥40mm or ejection fraction (EF) ≤60%, or new-onset atrial fibrillation, or resting pulmonary artery systolic pressure (PASP) >50mmHg
  • The patient with American Association of Thoracic Surgeons Score (STS) <8 has surgical indications evaluated by cardiac team
  • The patient has signed an informed consent form and agreed to regular follow-up for at least 1 year

Who cannot take part

  • inability to tolerate intraoperative or postoperative antithrombotic (anticoagulant or antiplate) therapy
  • acute myocardial infarction within 4 weeks before operation
  • acute cerebrovascular accident within 30 days before operation
  • acute peptic ulcer or upper gastrointestinal bleeding within 3 months before operation
  • The patient is participating in an experimental drug or other device study with an incomplete primary endpoint, or the patient is participating in an unfinished experimental drug or other device study that would clinically interfere with our study endpoints
  • active infective endocarditis especially occurring in the mitral valve area, or mitral valve perforation
  • rheumatic mitral valve disease, mitral stenosis or mitral valve orifice area < 4mm\^2
  • combined valve lesions requiring surgery, e.g. severe tricuspid regurgitation or aortic valve disease
  • the present of tumour, thrombus or redundant organisms in the heart chambers
  • Due to the presence of certain anatomical conditions, patient has a low success rate for TEER assessed by the operator and is not appropriate for enrolment. The conditions include but are not limited to the followings: 1) the venous approach is not suitable for operation, such as thrombus in the approach and small vein diameter; 2) severe calcification presents in the flap leaflet clamping area; 3) mitral valve cleft; 4) multiple regurgitant flow, especially in the internal and external union junction area; 5) Barlow disease; 6) leaflet length <7mm; 7) flail gap >10mm; 8) flail width >15mm
  • proposed implantation of heart failure device such as cardiac resynchronization therapy/cardiac resynchronization therapy defibrillator (CRT/CRT-D) or cardiac contractility modulation (CCM)
  • untreated severe coronary artery stenosis requiring coronary revascularization, or other cardiac macrovascular disease requiring surgery
  • hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or structural heart disease leading to heart failure other than dilated heart disease
  • severe pulmonary hypertension ( PASP >70 mmHg), or pulmonary hypertension associated with no-left heart disease, e.g. pulmonary arterial hypertension (PAH) etc
  • uncontrolled autoimmune connective tissue diseases especially Behcet's disease and systemic lupus erythematosus (SLE)
  • severe infections, septicaemia
  • severe hepatic insufficiency, e.g. acute severe hepatitis, decompensated cirrhosis ( Child-Pugh class C)
  • contraindication for TEE, e.g. oesophageal constriction, oesophageal tumour, oesophageal fistula, oesophageal varices, cervical vertebral instability, etc
  • contraindication for intravenous anaesthesia, e.g. allergy to anaesthetics
  • severe cardiac insufficiency ( NYHA class IV or lefr ventricular ejection fraction (LVEF) <20% ), end-stage heart failure status ( American College of Cardiology/American Heart Association (ACC/AHA) Stage D), relying on circulation aids or waiting for heart transplantation
  • severe renal insufficiency ( chronic kidney disease (CKD) stage 5: estimated glomerular filtration rate (eGFR) < 15 ml/min or dialysis)
  • uncontrolled diseases of the haematological system: acute gastrointestinal bleeding, intracranial haemorrhage or haemorrhage from other organs, acute pulmonary embolism or deep vein thrombosis, congenital or acquired haemorrhagic disease such as haemophilia, anaphylactic purpura and acute leukaemia, severe abnormalities in haematological parameters such as platelet count <20*10\^9/L and international normalized ratio (INR) >3
  • acute DMR, e.g. DMR caused by acute papillary muscle rupture
  • uncontrolled hyperthyroidism
  • amyloidosis
  • hypotensive state, shock ( systolic blood pressure < 90mmHg or mean arterial pressure <70 mmHg with tissue hypoperfusion and urine output < 30 ml/h)
  • pregnancy or breastfeeding
  • The patient does not sign an informed consent form
  • expected survival less than 1 year
  • The patient with poor compliance is not thought to complete follow-up visits
  • Due to other reasons the patient is not suitable for enrollment assessed by the researcher

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Mitral regurgitation

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To investigate the efficacy and safety of transcatheter mitral valve edge-to-edge repair (TEER) for severe degenerative mitral regurgitation (DMR) patients of low to intermediate surgery risk.

The group in the trial

  • TEER group

    Severe DMR patients of low to intermediate surgery risk who underwent TEER.

    Treatment: ultrasonic cardiography (UCG) and TEER

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Efficacy and Safety of TEER for Severe DMR Patients of Low to Intermediate Surgery Risk (TESLA-R)--a Multi-center, Prospective Cohort Study
Criteria questions
Built from NCT06162780, who can take part
Record updated
15 March 2024